Alizyme

Quick facts

Phase 2 pipeline

• ATL-104 · Diabetes
  ATL-104 is a glucagon receptor antagonist.
• ATL-962 · Diabetes
  ATL-962 is a glucagon receptor antagonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alizyme portfolio CI brief
• Alizyme pipeline updates RSS

Related

• Sector hub: All tracked pharma companies